Saroglitazar, a PPARα/γ dual agonist, has shown potential benefits in animal models of MASH and may decrease serum ALT concentrations and improve cardiometabolic profiles. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.